OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Cardiology is 72. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
LIPC variant in combined hypocholesterolaemia	832
Antibody treatment to deplete transthyretin amyloid deposits in the heart	535
Sacubitril–valsartan shows benefit in heart failure with ejection fraction of >40%	380
Intravascular imaging improves outcomes	362
Bariatric metabolic surgery more effective than GLP1R agonists in preventing congestive HF	336
Travelling with heart failure: risk assessment and practical recommendations	333
Aggregation of big tau disrupts microtubules and causes diastolic dysfunction	327
Screening for Helicobacter pylori infection in patients with cardiovascular and gastrointestinal disease	326
Takotsubo syndrome: pathophysiological insights and innovations in patient care	315
Neuroimmune axis of cardiovascular control: mechanisms and therapeutic implications	314
Genetics and mechanisms of thoracic aortic disease	265
Accelerated reduction in global cardiovascular disease is essential to achieve the Sustainable Development Goals	256
Changing epidemiology of congenital heart disease: effect on outcomes and quality of care in adults	252
Alternative defibrillation strategies improve outcomes	250
Factor XI inhibitors in patients with cardiovascular disease and a high risk of bleeding: a cautionary tale	248
Detection of subclinical hypertrophic cardiomyopathy	248
Defining iron deficiency in patients with heart failure	247
European guidelines for hypertension in 2024: a comparison of key recommendations for clinical practice	242
Maternal cardiovascular disorders before and during pregnancy and offspring cardiovascular risk across the life course	231
Think Aorta: aortic dissection awareness and perspectives from the patient	222
Electron microscopy of cardiac 3D nanodynamics: form, function, future	215
Hallmarks of cardiovascular ageing	212
Neuromodulation reduces inflammation in HFpEF	202
A fatty acid from mother’s milk drives cardiomyocyte maturation in newborn mice	196
CSDE1 regulates LDL receptor levels	191

Preparticipation screening reduces SCD in young athletes	190
LDL-cholesterol lowering with obicetrapib	185
No benefit of apoA-I infusion after myocardial infarction	179
Increased degradation of desmosomal proteins in ACM	179
Identifying leukocyte phenotypes by scRNA-seq to predict cardiovascular risk	179
Catheter ablation improves outcomes in patients with AF and end-stage HF	174
Decongestion in heart failure: medical and device therapies	170
Reactive oxygen species in hypertension	167
Tailored therapeutics for cardiomyopathies	167
Graded exercise therapy should not be recommended for patients with post-exertional malaise	138
Colchicine in acute coronary syndromes: the present and the possible future	136
Targeting immune cell recruitment in atherosclerosis	130
Extracellular matrix in vascular homeostasis and disease	129
Prevention of atherosclerosis from childhood	126
Treatment of mild chronic hypertension in pregnancy reduces pre-eclampsia risk	122
The oral microbiome in the pathophysiology of cardiovascular disease	122
Donor macrophages influence rejection of transplanted hearts	119
Modelling pre-eclampsia and its cardiovascular effects	113
Reply to ‘Graded exercise therapy should not be recommended for patients with post-exertional malaise’	109
RNA interference lowers triglyceride levels	108
Cardiac sarcomere turnover by unidirectional replacement of proteins	107
Unlocking excellence in health care: the power of inclusive and sensitive language in medicine	107
Bempedoic acid prevents cardiovascular events in statin-intolerant patients	104
Evidence does not support the reduction of added sugar intake from all food sources	101
Promising novel siRNA for the treatment of hypertension	99
Not a spectator sport: improving participation of Black patients in cardiovascular clinical trials	97
Semaglutide is beneficial in patients with HFpEF and obesity	97
An epigenome editing approach induces durable silencing of Pcsk9	94
Global epidemiology of heart failure	94
Single-cell profiles of CHD and CM	93
Computational modelling of cardiovascular pathophysiology to risk stratify commercial spaceflight	90
BP management with a village-doctor-led strategy	90
Novel factor XIa inhibitor reduces bleeding compared with apixaban in atrial fibrillation	89
Simvastatin protects against endothelial dysfunction via epigenetic mechanisms	88
Author Correction: The contribution of amyloid deposition in the aortic valve to calcification and aortic stenosis	87
Development of a miniature, bioresorbable, light-activated pacemaker	87
The gut metabolite imidazole propionate is a potential biomarker of and therapeutic target for atherosclerosis	86
Heart transplantation: advances in expanding the donor pool and xenotransplantation	85
The role of the molecular autopsy in sudden cardiac death in young individuals	85
Clonal haematopoiesis in cardiovascular disease: prognostic role and novel therapeutic target	85
Efferocytosis in atherosclerosis	81
Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology	79
CNR1 antagonism attenuates cannabis-induced atherosclerosis	79
Low alcohol intake might lower CVD risk by reducing stress-related brain activity	78
Fibroblast-like cells promote plaque stability in response to anti-IL-1β therapy	75
Gut bacteria can break down cholesterol	72
Baxdrostat beneficial in uncontrolled or resistant hypertension	72